[www.niftyviews.com:23913] Fwd: Nifty Fut (Feb): 7215-7110 Zone Very Crucial---

[Asis Ghosh]

 Forwarded Message 
Subject:Nifty Fut (Feb): 7215-7110 Zone Very Crucial---
Date:   Wed, 10 Feb 2016 09:05:13 +0530
From:   Asis Ghosh 
Reply-To:   asis...@gmail.com



*NF has to sustain above 7370-7410 zone for any strength up to 7590-7685*
*Otherwise, 7110-6850 may be on the card*

Apart from Oil & China, probable US recession
And EU credit problem is now the prime concern for the global market

Yellen testimony (likely to be dovish) may provide some temporary relief

But, forthcoming budget session may be another washout except passage of 
budget

as probability of political consensus for passage of crucial reform bills
including GST is very little


*Trading Levels: Nifty Fut (Feb)*

SGX-NF: 7250 (CMP)

NSE-NF: 7330 (LTP)

SL (+/-) 10 POINTS  FROM SLR


For Intraday Swing  Trader  
T1  T2  T3  T4  T5  SLR
Strong > 72157235-285*   7305-3457385-411*   
7445-4907540-590*   <7195

Weak <   71957160-110*   7040-7000   6940-885*   
6835-7806745-700>7215









FOR ConservativePositional  Trader  













T1  T2  T3  T4  T5  SLR
Strong > 72157285*   73457411*   74907590-685
<7195

Weak <   71957110*   70006885*   67456700-550
>7215



Technically, NF may be in the 2-nd wave (daily EW cycle) and the 
extended target of the same is around 7215. Consecutive closing below 
this 7215 zone, NF may further fall to 7110-7000-6850 level. In the 
alternative scenario, if NF failed to sustain below 7215, we may see 
some relief rally up to 7370-7410* and 7540-7590 & 7685 zone.


*Analytical Charts:*














--
Thanks & Regards,

Asis Ghosh
(asisghosh.blogspot.com)
NCFM-TA Certified



--
Kindly email stock reports at 

STOCKRESEARCHER@googlegroups.com 


For sharing knowledge

-- NIFTYVIEWS.COM NOW A FREE OPEN SOURCE WEBSITE.

http://www.niftyviews.com/ 



Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture.The administrator of 
www.Niftyviews.com just provide a platform for the authors to express their opinion 
and take no guarantee for the genuineness of the same."ANY member of this forum 
doesnt prepare or publish any research report; or ii. provide research report; or 
iii. make 'buy/sell/hold' recommendation; or iv. give price target;
--- 
You received this message because you are subscribed to the Google Groups "Niftyviews.com" group.

To unsubscribe from this group and stop receiving emails from it, send an email 
to stockresearcher+unsubscr...@googlegroups.com.
For more options, visit https://groups.google.com/d/optout.

[www.niftyviews.com:23914] PNB-Open Or Closed?

[Rajiv Handa]

 of clients…PNB was cheap at 150, it is
cheaper at 100 and it is now further cheaper at 88! Let me take you back to
the limits theorem that we learnt in mathematics…Since reported stressed
assets to net-worth is 130% and including all sorts of regulatory
forbearance it is at 170%, then as we have learnt – when book value tends
towards zero P/BV will tend towards infinity!
Won’t even touch this with a barge pole…


Let me end on a lighter note…This is the cartoon which is floating in some
newspapers today!

[image: IMG-20160209-WA0022]

-- 
Kindly email stock reports at 

STOCKRESEARCHER@googlegroups.com 

For sharing knowledge

-- NIFTYVIEWS.COM NOW A FREE OPEN SOURCE WEBSITE.

http://www.niftyviews.com/ 


Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture.The 
administrator of www.Niftyviews.com just provide a platform for the authors to 
express their opinion and take no guarantee for the genuineness of the 
same."ANY member of this forum doesnt prepare or publish any research report; 
or ii. provide research report; or iii. make 'buy/sell/hold' recommendation; or 
iv. give price target;
--- 
You received this message because you are subscribed to the Google Groups 
"Niftyviews.com" group.
To unsubscribe from this group and stop receiving emails from it, send an email 
to stockresearcher+unsubscr...@googlegroups.com.
For more options, visit https://groups.google.com/d/optout.

[www.niftyviews.com:23919] Is Indian Pharma trying To Fool the USFDA?...Capitalmind

[Rajiv Handa]

On the 29-Jan-16 (Tuesday), the *US FDA issued a Warning Letter to IPCA
Laboratories. *

The letter was in relation to the:

   1.
*Inspection performed during July, 2014 at Ratlam (Madhya Pradesh)
   observations in Form FDA 483 which subsequently resulted into issuance of
   import alert on the said manufacturing unit by the US FDA on 22-Jan-15 *
   2. *Inspection of the formulations manufacturing units situated at SEZ
   Indore (Pithampur) and Piparia (Silvassa) which resulted in **Form FDA
   483 to the said manufacturing units and had issued import alert on
   24-Mar-15. *

IPCA confirmed the receipt of the US FDA Warning Letter on the 1-Feb-16
(Friday) – refer here for the confirmation

This is what the company had to say about it:

We refer to our letters dated 24th July, 2014, 23rd January, 2015 and 25th
March, 2015 informing you about the US FDA inspections at our manufacturing
units situated at Ratlam (Madhya Pradesh), SEZ Indore (Pithampur) and
Piparia (Silvassa), during which inspections these manufacturing units
received certain inspection observations in Form 483 and which subsequently
resulted in issuance of import aiert on these manufacturing units.

We wish to inform you that US FDA has now issued a warning letter to these
manufacturing units. We have already informed you that the Company has
voluntarily suspended shipments of its APls and formulations for the US
market till US FDA inspection observations are resolved. Therefore, since
July 2014 the Company has not shipped any APls or formulations to US market
except the products which are exempted from import alert.

The Company has responded to the US FDA inspection observations with its
remediation measures and has been since working also with external
consultants to ensure that its remedial activities are undertaken in a
proper and timely manner.

Since the inspection, the Company has regularly communicated with US FDA
with periodic updates on remedial measures undertaken. The Company is fully
committed in resolving this issue at the earliest.

The Company is also committed to its philosophy of highest quality in
manufacturing, operations, systems integrity and cGMP culture.

Today, the US FDA Posted the Warning Letter issued to IPCA (refer here for
the Original Copy

).
Here is the full copy of the Warning Letter:

Ipca Laboratories Limited 1/29/16
[image: Department of Health and Human Services logo]Department of Health
and Human Services Public Health Service
Food and Drug Administration
Silver Spring, MD  20993


*Warning Letter*



*Via
UPS
*
*WL: 320-16-07*
January 29, 2016

Mr. Premchand Godha
Chairman & Managing Director
Ipca Laboratories Ltd.
48, Kandivli Industrial Estate
Kandivli (West), Mumbai 400 067
India
Dear Mr. Godha:
In 2014, the U.S. Food and Drug Administration (FDA) inspected three Ipca
pharmaceutical manufacturing facilities.

   1. July 14–18: P.O. No. 33 Village Sejavata, Ratlam 457 002 Madhya
   Pradesh (Ratlam facility)
   2. October 13–17: 1 Pharma Zone, SEZ Phase II, Sector 3, District Dhar,
   Pithampur, Madhya Pradesh (Pithampur facility)
   3. December 1–19: Plot 65 & 99, Danudyog Industrial Estate, Piparia
   Silvassa 396 230 (Union Territory of Dadra & Nagar Haveli) (Piparia
   Silvassa facility)

At your Ratlam facility, we identified significant deviations from current
good manufacturing practice (CGMP) for active pharmaceutical ingredients
(API). At your Pithampur and Piparia Silvassa facilities, we identified
significant violations of CGMP for finished pharmaceuticals, Title 21, Code
of Federal Regulations, Parts 210 and 211.

These deviations and violations cause your drugs to be adulterated within
the meaning of Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic
Act (the FD Act), 21 U.S.C. 351(a)(2)(B). The methods used in, or the
facilities or controls used for, their manufacture, processing, packing, or
holding do not conform to, or are not operated or administered in
conformity with, CGMP.

We reviewed your firm’s responses of August 8 and November 7, 2014, and
January 9, 2015, in detail for all three sites and acknowledge receipt of
subsequent responses.
We observed specific deviations and violations during the inspections,
including, but not limited to, the following.

*A.**Ratlam facility (**FEI: 3002807297)*

*1.Failure to have computerized systems with sufficient controls to
prevent unauthorized access or changes to data*.

During the inspection, FDA investigators discovered a lack of basic
laboratory controls to prevent changes to your firm’s electronically stored
data. Your firm relied on incomplete records to evaluate the quality of
your drugs and to determine whether your drugs conformed with established
specifications and standards.

Our investigators found that your firm routinely re-tested samples without